STAMM; Simon

Patent Applications and Registrations

Patent applications and USPTO patent grants for STAMM; Simon.The latest application filed is for "pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compound".

Company Profile

2.12.14

STAMM; Simon - Allschwil CH
Stamm; Simon - Brakel DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutical Composition Comprising A Tetrahydropyrazolopyrimidinone Compound App 20220265658 - AMBUEHL; Michael ; et al.	2022-08-25
Connector for electric vehicle Grant D949,797 - Stamm , et al. April 26, 2	2022-04-26
C5a Receptor Modulators App 20210122736 - FROIDEVAUX; Sylvie ; et al.	2021-04-29
2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one Derivatives And Related Compounds As C5a Receptor Modulators For Treating Vasculitis And Inflammatory Diseases App 20200369672 - FROIDEVAUX; Sylvie ; et al.	2020-11-26
C5a Receptor Modulators App 20200347029 - FROIDEVAUX; Sylvie ; et al.	2020-11-05
Triazole compounds as T-type calcium channel blockers Grant 10,246,426 - Bezencon , et al.	2019-04-02
Pyrazole compounds and their use as T-type calcium channel blockers Grant 10,065,929 - Siegrist , et al. September 4, 2	2018-09-04
Triazole Compounds As T-type Calcium Channel Blockers App 20180230109 - BEZENCON; Olivier ; et al.	2018-08-16
Pyrazole Compounds And Their Use As T-type Calcium Channel Blockers App 20180105496 - SIEGRIST; Romain ; et al.	2018-04-19
Pyrazole compounds and their use as T-type calcium channel blockers Grant 9,932,314 - Siegrist , et al. April 3, 2	2018-04-03
Indole carboxamide derivatives as P2X7 receptor antagonist Grant 9,718,774 - Hilpert , et al. August 1, 2	2017-08-01
Pyrazole Compounds And Their Use As T-type Calcium Channel Blockers App 20170096399 - SIEGRIST; Romain ; et al.	2017-04-06
Indole carboxamide derivatives as P2X.sub.7 receptor antagonists Grant 9,556,117 - Hilpert , et al. January 31, 2	2017-01-31
Heterocyclic amide derivatives as P2X7 receptor antagonists Grant 9,409,917 - Hilpert , et al. August 9, 2	2016-08-09
Heterocyclic amide derivatives as P2X7 receptor antagonists Grant 9,388,197 - Hilpert , et al. July 12, 2	2016-07-12
Heterocyclic amide derivatives as P2X.sub.7 receptor antagonists Grant 9,388,198 - Hilpert , et al. July 12, 2	2016-07-12
Heterocyclic amide derivatives as P2X7 receptor antagonists Grant 9,221,832 - Hilpert , et al. December 29, 2	2015-12-29
Heterocyclic Amide Derivatives As P2x7 Receptor Antagonists App 20150361097 - HILPERT; KURT ; et al.	2015-12-17
Heterocyclic Amide Derivatives As P2x7 Receptor Antagonists App 20150361096 - HILPERT; KURT ; et al.	2015-12-17
Indole Carboxamide Derivatives As P2x7 Receptor Antagonists App 20150344425 - HILPERT; KURT ; et al.	2015-12-03
Indole Carboxamide Derivatives As P2x7 Receptor Antagonist App 20150322008 - HILPERT; KURT ; et al.	2015-11-12
Heterocyclic Amide Derivatives As P2x7 Receptor Antagonists App 20150025075 - Hilpert; Kurt ; et al.	2015-01-22
Heterocyclic Amide Derivatives As P2x7 Receptor Antagonists App 20140163035 - Hilpert; Kurt ; et al.	2014-06-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.